Talquetamab vs Real-World Physician's Choice in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-Cell Maturation Antigen Therapy: Analyses of MonumenTAL-1 vs LocoMMotion/MoMMent

被引：0

作者：

Mateos Manteca, Maria-Victoria ^{[1
]}

Jakubowiak, Andrzej ^{[2
]}

Einsele, Hermann ^{[3
]}

Schinke, Carolina ^{[4
]}

Besemer, Britta ^{[5
]}

Anguille, Sebastien ^{[6
]}

Manier, Salomon ^{[7
]}

Rasche, Leo ^{[8
]}

Goldschmidt, Hartmut ^{[9
]}

van de Donk, Niels ^{[10
,11
]}

Perrot, Aurore ^{[12
]}

Teipel, Raphael ^{[13
]}

Karlin, Lionel ^{[14
]}

Scheid, Christof ^{[15
]}

San-Miguel, Jesus ^{[16
]}

Pawlyn, Charlotte ^{[17
,18
]}

Martinez-Lopez, Joaquin ^{[19
]}

Cavo, Michele ^{[20
]}

Diels, Joris ^{[21
]}

Renaud, Thomas ^{[22
]}

Orel, Oleksiy ^{[23
]}

Cabrieto, Jedelyn ^{[21
]}

Perualila, Nolen ^{[21
]}

Weisel, Katja ^{[24
]}

Moreau, Philippe ^{[25
]}

机构：

[1] Univ Hosp Salamanca, Inst Biomed Res Salamanca IBSAL, CIBERONC, Salamanca, Spain

[2] Univ Chicago, Chicago, IL USA

[3] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[4] Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR USA

[5] Univ Tubingen, Tubingen, Germany

[6] Univ Antwerp, Antwerp Univ Hosp, Ctr Cell Therapy & Regenerat Med, Vaccine & Infect Dis Inst, Antwerp, Belgium

[7] Univ Lille, CHU Lille, Lille, France

[8] Univ Hosp Wurzburg, Wurzburg, Germany

[9] Univ Hosp Heidelberg, GMMG Study Grp, Dept Internal Med 5, Heidelberg, Germany

[10] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Hematol, Amsterdam, Netherlands

[11] Canc Ctr Amsterdam, Amsterdam, Netherlands

[12] Univ Toulouse, Serv Hematol, Toulouse, France

[13] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, Dresden, Germany

[14] Ctr Hosp Lyon Sud, Lyon, France

[15] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[16] Clin Univ Navarra, Navarra, Spain

[17] Inst Canc Res, London, England

[18] Royal Marsden NHS Fdn Trust, London, England

[19] Univ Complutense Madrid, CNIO Clin Res Unit H12O, CIBERONC, Dept Hematol,Hosp 12 Octubre, Madrid, Spain

[20] Univ Bologna, IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[21] Janssen Pharmaceut NV, Beerse, Belgium

[22] Janssen Res & Dev, Raritan, NJ USA

[23] Janssen Cilag GmbH, Neuss, Germany

[24] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[25] Univ Hosp Hotel Dieu, Hematol Dept, Beirut, Lebanon

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-050

引用

页码：S69 / S70

页数：2

共 50 条

[31] Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myeloma
Giri, Smith
Bal, Susan
Godby, Kelly N.
Ravi, Gayathri
Clark, Deanna
Ubersax, Clare
Cooley, Abigail
White, Priscila
Rangarajan, Sunil
Williams, Grant R.
Costa, Luciano J.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (04) : E153 - E155
[32] Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: Pooled Analysis From MagnetisMM Studies
Nooka, Ajay K.
Lesokhin, Alexander M.
Mohty, Mohamad
Niesvizky, Ruben
Maisel, Christopher
Arnulf, Bertrand
Larson, Sarah M.
Varshavsky-Yanovsky, Asya Nina
Leleu, Xavier
Karlin, Lionel
Vesole, David H.
Bahlis, Nizar J.
Fernandez de Larrea, Carlos
Raje, Noopur
Leip, Eric
Conte, Umberto
Elmeliegy, Mohamed
Viqueira, Andrea
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S496 - S497
[33] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
Cortes-Selva, Diana
Casneuf, Tineke
Vishwamitra, Deeksha
Stein, Sarah
Perova, Tatiana
Skerget, Sheri
Ramos, Elena
van Steenbergen, Laure
De Maeyer, Dries
Boominathan, Rengasamy
Lau, Onsay
Davis, Cuc
Banerjee, Arnob
Stephenson, Tara
Uhlar, Clarissa M.
Kobos, Rachel
Goldberg, Jenna D.
Pei, Lixia
Trancucci, Danielle
Girgis, Suzette
Lin, Shun Xin Wang
Wu, Liviawati S.
Moreau, Philippe
Usmani, Saad
Bahlis, Nizar Jacques
Van de Donk, Niels W. C. J.
Verona, Raluca
BLOOD, 2022, 140
[34] CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
Madduri, Deepu
Berdeja, Jesus G.
Usmani, Saad Z.
Jakubowiak, Andrzej
Agha, Mounzer
Cohen, Adam D.
Stewart, A. Keith
Hari, Parameswaran
Htut, Myo
O'Donnell, Elizabeth
Munshi, Nikhil C.
Avigan, David E.
Deol, Abhinav
Lesokhin, Alexander M.
Singh, Indrajeet
Zudaire, Enrique
Yeh, Tzu-Min
Allred, Alicia J.
Olyslager, Yunsi
Banerjee, Arnob
Goldberg, Jenna D.
Schecter, Jordan M.
Jackson, Carolyn C.
Deraedt, William
Zhuang, Sen Hong
Infante, Jeffrey R.
Geng, Dong
Wu, Xiaoling
Carrasco, Marlene J.
Akram, Muhammad
Hossain, Farah
Rizvi, Syed
Fan, Frank
Jagannath, Sundar
Lin, Yi
Martin, Thomas, III
BLOOD, 2020, 136
[35] Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma
Chihara, Dai
Liao, Laura
Tkacz, Joseph
Franco, Anjali
Lewing, Benjamin
Kilgore, Karl M.
Nastoupil, Loretta J.
Chen, Lei
BLOOD, 2023, 142 (12) : 1047 - 1055
[36] Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England
Fox, Christopher P.
Townsend, William
Gribben, John G.
Menne, Tobias
Kalakonda, Nagesh
Williams, Paula
Toron, Farah
Tyas, Emma
Cooper, Miranda
Rickards, Joshua
Radford, John
EJHAEM, 2024, 5 (05): : 992 - 997
[37] Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
Nooka, Ajay K.
Lesokhin, Alexander M.
Mohty, Mohamad
Niesvizky, Ruben
Maisel, Christopher
Arnulf, Bertrand
Larson, Sarah Marie
Yanovsky, Asya Varshavsky
Leleu, Xavier P.
Karlin, Lionel
Vesole, David H.
Bahlis, Nizar J.
de Larrea, Carlos Fernandez
Raje, Noopur S.
Leip, Eric
Conte, Umberto
Elmeliegy, Mohamed
Viqueira, Andrea
Manier, Salomon
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[38] Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT)
Venkatesh, Priyanka
Atrash, Shebli
Paul, Barry
Alkharabsheh, Omar
Afrough, Aimaz
Mahmoudjafari, Zahra
Mushtaq, Muhammad Umair
Hashmi, Hamza
Davis, James A.
Abdallah, Al-Ola A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[39] Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Gagelmann, Nico
Dima, Danai
Merz, Maximilian
Hashmi, Hamza
Ahmed, Nausheen
Tovar, Natalia
Oliver-Caldes, Aina
Stoelzel, Friedrich
Rathje, Kristin
Fischer, Luise
Born, Patrick
Schaefer, Lisa
Albici, Anca-Maria
Schub, Natalie
Kfir-Erenfeld, Shlomit
Assayag, Miri
Asherie, Nathalie
Wulf, Gerald Georg
Kharboutli, Soraya
Mueller, Fabian
Shune, Leyla
Davis, James A.
Anwer, Faiz
Vucinic, Vladan
Platzbecker, Uwe
Ayuk, Francis
Kroeger, Nicolaus
Khouri, Jack
Gurnari, Carmelo
McGuirk, Joseph
Stepensky, Polina
Abdallah, Al-Ola
de Larrea, Carlos Fernandez
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (14) : 1665 - 1675
[40] Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy
Bujarski, Sean
Udd, Kyle
Soof, Camilia
Chen, Haiming
Spektor, Tanya M.
Safaie, Tahmineh
Li, Mingjie
Stern, Joshua
Wang, Cathy
Xu, Ning
Emamy-Sadr, Marsiye
Swift, Regina
Rahbari, Ashkon
Patil, Saurabh
Souther, Eric
Regidor, Bernard
Sutanto, Christine
Berenson, James R.
TARGETED ONCOLOGY, 2021, 16 (04) : 503 - 515

← 1 2 3 4 5 →